Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

[1]  B. Cho,et al.  Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma , 2014, Annals of Hematology.

[2]  J. Miguel,et al.  Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease , 2012, Haematologica.

[3]  Michael L. Wang,et al.  CR represents an early index of potential long survival in multiple myeloma , 2010, Bone Marrow Transplantation.

[4]  P. Moreau,et al.  Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Barlogie,et al.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. , 2009, Blood.

[6]  J. H. Lee,et al.  Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  B. Barlogie,et al.  Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma , 2008, Cancer.

[8]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[9]  R. Champlin,et al.  Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma , 2004, Bone Marrow Transplantation.

[10]  Santhosh K. P. Kumar,et al.  High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy , 2004, Bone Marrow Transplantation.

[11]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[12]  S. Singhal,et al.  Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma , 2002, Bone Marrow Transplantation.

[13]  R. Champlin,et al.  Impact of complete remission with intensive therapy in patients with responsive multiple myeloma , 2001, Bone Marrow Transplantation.

[14]  S. Rives,et al.  High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution , 2000, Bone Marrow Transplantation.

[15]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[16]  J. Crowley,et al.  High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants , 1994 .

[17]  P. Hari,et al.  Cure of multiple myeloma – more hype, less reality , 2006, Bone Marrow Transplantation.

[18]  E. Giné,et al.  High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission , 2004, Bone Marrow Transplantation.

[19]  H. Johnsen,et al.  Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. , 2000, Blood.